# Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension

> **NCT00765674** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 1191 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Aliskiren
- **DRUG:** Amlodipine
- **DRUG:** Hydrochlorothiazide (HCTZ)
- **DRUG:** Placebo
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00765674
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 1191 (ACTUAL)
- **Last updated:** 2011-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00765674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00765674, "Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00765674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*